Successful treatment with splenectomy and interferon alpha against recurred hemophagocytic syndrome in remission state of anaplastic large cell lymphoma following high-dose therapy and autologous peripheral blood stem cell transplantation

Eur J Haematol. 2005 Mar;74(3):259-62. doi: 10.1111/j.1600-0609.2004.00359.x.


A 25-yr-old man had been diagnosed as having CD30(+) anaplastic large cell lymphoma associated with hemophagocytic syndrome (HS). He received aggressive frontline chemotherapies and consolidation with autologous peripheral blood stem cell transplantation (PBSCT) following high-dose chemotherapy combined with splenic irradiation (720 cGy in fraction of 180 cGy). However, HS recurred on day 50 of PBSCT without radiologic evidence of lymphoma relapse. On day 56 of PBSCT, splenectomy was performed and pathology showed massive sinusoidal infiltration of histiocytes. On day 68 of PBSCT, administration of interferon alpha was started and maintained for 24 months. HS was completely resolved and he has been alive well and in complete remission (CR), 60 months after initial diagnosis.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Disease-Free Survival
  • Histiocytosis, Non-Langerhans-Cell / etiology
  • Histiocytosis, Non-Langerhans-Cell / pathology
  • Histiocytosis, Non-Langerhans-Cell / therapy*
  • Humans
  • Interferon-alpha / therapeutic use*
  • Lymphoma, Large-Cell, Anaplastic / complications*
  • Lymphoma, Large-Cell, Anaplastic / pathology
  • Lymphoma, Large-Cell, Anaplastic / therapy
  • Male
  • Peripheral Blood Stem Cell Transplantation
  • Recurrence
  • Remission Induction / methods
  • Splenectomy*


  • Interferon-alpha